Literature DB >> 10786654

Uses of granulocyte-macrophage colony-stimulating factor in vaccine development.

T L Warren1, G J Weiner.   

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a potent cytokine capable of inducing differentiation, proliferation, and activation of a variety of immunologically active cell populations. In addition to its effects on stimulating granulocytic hematopoiesis, it also facilitates development of both humoral and cellular mediated immunity. Accordingly, strategies involving the use of GM-CSF as a vaccine adjuvant have attracted considerable attention. These strategies include the systemic administration of soluble GM-CSF with an immunogen, and also its use as part of gene therapy approaches to immunization. Because of the potency of this cytokine as an immune adjuvant, particular interest has focused on its use to overcome poorly immunogenic antigens such as those associated with intracellular infections and cancer. This review focuses on recent advances in the use of GM-CSF as a vaccine adjuvant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786654     DOI: 10.1097/00062752-200005000-00007

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  13 in total

1.  Effect of active immunization against a recombinant mouse granulocyte-macrophage colony-stimulating factor/somatostatin fusion protein on the growth of mice.

Authors:  Bingbing Wu; Ruili Qi; Bin Li; Taoyan Yuan; Heshan Liu; Jun He; Zhiwei Lin; Weifen Li; Yan Fu; Dong Niu
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

2.  Castration-resistant prostate cancer: new science and therapeutic prospects.

Authors:  Joaquim Bellmunt; William K Oh
Journal:  Ther Adv Med Oncol       Date:  2010-05       Impact factor: 8.168

3.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 4.  Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.

Authors:  Ting-Wei Yu; Ho-Yen Chueh; Ching-Chou Tsai; Cheng-Tao Lin; Jiantai Timothy Qiu
Journal:  Hum Vaccin Immunother       Date:  2016-08-25       Impact factor: 3.452

5.  The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis.

Authors:  Alaa Bassuny Ismael; Dalila Sekkai; Christine Collin; Daniel Bout; Marie-Noëlle Mévélec
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

6.  Acute exercise enhancement of pneumococcal vaccination response: a randomised controlled trial of weaker and stronger immune response.

Authors:  Kate M Edwards; Meredith A Pung; Lianne M Tomfohr; Michael G Ziegler; John P Campbell; Mark T Drayson; Paul J Mills
Journal:  Vaccine       Date:  2012-08-22       Impact factor: 3.641

7.  Successful topical respiratory tract immunization of primates against Ebola virus.

Authors:  Alexander Bukreyev; Pierre E Rollin; Mallory K Tate; Lijuan Yang; Sherif R Zaki; Wun-Ju Shieh; Brian R Murphy; Peter L Collins; Anthony Sanchez
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

8.  Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection.

Authors:  Pierre Antoine Brown; Jonathan B Angel
Journal:  J Immune Based Ther Vaccines       Date:  2005-05-18

9.  Innate Response Activator (IRA) B Cells Reside in Human Tonsils and Internalize Bacteria In Vitro.

Authors:  Nico Chiappini; Rocco Cantisani; Laura Pancotto; Paolo Ruggiero; Domenico Rosa; Andrea Manetti; Antonio Romano; Francesca Montagnani; Sylvie Bertholet; Flora Castellino; Giuseppe Del Giudice
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

Review 10.  mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Authors:  Sandra Van Lint; Carlo Heirman; Kris Thielemans; Karine Breckpot
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.